Norgine B.V. (“Norgine”) has announced the acquisition of Azanta A/S, a specialty biopharmaceutical company operating within women’s healthcare, oncology and addiction medicine. Azanta’s portfolio of products comprises, among other things, Angusta® for labour induction and Nimorazole, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy.
Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand and has a strong track-record of successfully bringing products to market across Europe. Azanta A/S is headquartered in Denmark with pharmaceutical sales subsidiaries in the other Nordic countries and in France. The acquisition further strengthens Norgine’s position as a leading European specialist pharmaceutical company.
Building on Bech-Bruun’s unique position in the transaction and life science markets, the Bech-Bruun team led by partners Thomas Gjøl-Trønning, M&A, and Martin Dræbye Gantzhorn, IP & Life Science, had the pleasure of assisting Norgine’s deal team. We congratulate the parties on the transaction.
Read more about the acquisition here.